Evidence summaries (no coverage rules present) — aggregated evidence summaries without explicit coverage nodes.
Tear Film Biomarkers (e.g., Goblet Cell-Specific MUC5AC and Interleukin-8): Akpek et al (2020) conducted a prospective observational case-control study (n=62) assessing tear MUC5AC and cytokines for distinguishing Sjögren versus non-Sjögren dry eye; findings showed reduced MUC5AC and higher IL-8 associated with Sjögren diagnosis, suggesting potential diagnostic value but not yet established for routine clinical use.
InflammaDry (MMP-9): Multiple sources provide mixed evidence. Sambursky (2016) retrospective chart review (n=100) reported that InflammaDry identified elevated MMP-9 in 60% of symptomatic patients and changes in treatment management with symptomatic improvement at ~90 days, but study limitations include retrospective design and lack of control. Dohlman et al (2016) and AAO (2018) note that point-of-care MMP-9 testing can aid diagnosis and disease monitoring, but it does not differentiate dry eye from other inflammatory ocular surface diseases.
Tear Osmolarity Measurement: Devices that measure tear osmolarity are commercially available and cited as objective parameters to stage DED severity in guideline-based management (Foulks et al, 2015); evidence supports use as part of comprehensive assessment but no single gold-standard diagnostic test exists.
InflammaDry Guideline Context: The 2015 consensus guideline for Sjögren-associated DED (Foulks et al) recommended use of objective parameters including tear osmolarity and measures of ocular surface inflammation in staging disease, but did not specifically endorse routine MMP-9 measurement.
Intense Pulsed Light (IPL): Systematic reviews and RCT evidence are limited and of low/very low certainty. Small RCTs (total 3 trials, 114 adults) showed inconsistent effects on symptoms; a 2023 meta-analysis (Qin et al) including many studies reported improvements in symptom scores and TBUT but heterogeneity, risk of bias, variable protocols, and incomplete adverse event reporting limit conclusions. Overall, evidence for IPL in meibomian-gland dysfunction–related DED is scarce/low certainty and clinical value remains uncertain.
Etanercept and Systemic Cytokine Therapy: Systematic review (Shih et al, 2017) found that subcutaneous etanercept did not improve dry eye outcomes compared to placebo; authors noted systemic cytokine therapies have not produced encouraging ocular results and highlighted need for biomarker-informed trials.
Minor Salivary Gland Autotransplantation: Case series and uncontrolled reports (Wakamatsu et al, 2017) describe symptomatic and objective improvements in severe cases, but major clinical reviews and UpToDate do not list this as an established therapy; evidence limited to small, nonrandomized studies.
Botulinum Toxin: Small, short-term studies suggest potential benefit for intractable DED, but data are preliminary (small n, short follow-up) and UpToDate does not mention botulinum toxin as an established option.
Cross-Linked Hyaluronic Acid Gel Occlusive Devices: Single-arm, open-label studies report some positive findings but lack control groups; UpToDate does not list as standard therapy and evidence is insufficient.
Moxibustion, Acupuncture, Auricular Acupressure: Systematic reviews and meta-analyses report some positive signals (e.g., acupuncture meta-analysis of 21 RCTs; auricular acupressure meta-analysis of 7 RCTs) showing improvements in TBUT, Schirmer, or symptom scores versus artificial tears, but studies vary in quality, and reviewers conclude that higher-quality RCTs are needed to confirm benefits.
Androgen and Hormone Replacement Therapies: Systematic reviews (Wang & Deng 2020; Dang et al 2020) report mixed or transient findings; some short-term improvements noted but overall evidence is inconclusive and major guidance documents (UpToDate, AAO PPP) do not endorse ART/HRT as established management.
Topical Omega-3 Fatty Acid Eyedrops: Limited human studies (n small) suggest potential improvement in ocular surface staining and TBUT, but evidence base is sparse; by contrast, large RCTs of oral omega-3 supplementation showed no benefit over placebo.
Rituximab and Other Systemic Immunomodulators: RCT evidence (Devauchelle-Pensec et al, 2014) showed no significant benefit of rituximab for primary Sjögren's syndrome at 24 weeks for primary endpoints, although some early symptomatic improvements were observed; overall efficacy for dry eye is not established.
Novel Biologic/Regenerative Approaches (e.g., mesenchymal stem cells, TEMPO-oxidized sacchachitin nanofibers with PRP): Early-stage and heterogeneous reports exist but robust RCT evidence is lacking; clinical effectiveness remains unproven.
Clinical Implication: Across multiple modalities, evidence ranges from preliminary/low-certainty positive signals to negative large trials (e.g., oral omega-3). Several biomarkers and point-of-care tests may aid assessment or phenotyping of DED (tear osmolarity, MMP-9, tear MUC5AC), but none constitute a definitive standalone diagnostic standard. Many novel interventions require higher-quality randomized trials with standardized outcomes and safety reporting before they can be considered established therapies.